Entvin

About Entvin

Entvin provides AI-powered solutions that automate the generation of regulatory and scientific reports for pharmaceutical R&D, reducing report creation time from weeks to just minutes. By integrating with global regulatory databases and leveraging proprietary LLM models, Entvin enhances compliance and accelerates drug development timelines for generic pharma and biologics.

```xml <problem> Pharmaceutical R&D teams, particularly those focused on generic drugs and biologics, face challenges in navigating disparate global regulatory and scientific data sources. The process of compiling comprehensive regulatory and scientific reports is time-intensive, often taking weeks to complete, which delays drug development timelines. </problem> <solution> Entvin provides an AI-powered platform that automates the generation of regulatory and scientific reports for pharmaceutical R&D, significantly reducing report creation time. The platform integrates with global regulatory databases, scientific literature repositories, and patent databases, providing a unified interface for accessing real-time updates. By leveraging proprietary large language models (LLMs), Entvin intelligently extracts relevant information from documents, automatically updates reports as new information becomes available, and offers data-backed recommendations for literature review and experimental designs. This enables R&D teams to accelerate drug development, enhance compliance, and improve research quality. </solution> <features> - Automated R&D report generation, reducing creation time from weeks to minutes - Integration with major regulatory databases (FDA, EMA, PMDA, etc.) for real-time updates - Access to vast scientific literature repositories and patent databases - AI-driven R&D assistant for data-backed recommendations and insights - Secure, private cloud environment for hyper-secure deployment - SOC2, ISO, HIPAA, and GDPR certifications for regulatory compliance - Secure user data management with robust security for user activity logs and data </features> <target_audience> Entvin primarily targets R&D teams in generic pharmaceutical and biologics companies, as well as formulation scientists and regulatory affairs professionals. </target_audience> <revenue_model> Entvin operates on a subscription-based model, offering tiered pricing plans based on usage and features. </revenue_model> ```

What does Entvin do?

Entvin provides AI-powered solutions that automate the generation of regulatory and scientific reports for pharmaceutical R&D, reducing report creation time from weeks to just minutes. By integrating with global regulatory databases and leveraging proprietary LLM models, Entvin enhances compliance and accelerates drug development timelines for generic pharma and biologics.

Where is Entvin located?

Entvin is based in San Francisco, United States.

When was Entvin founded?

Entvin was founded in 2022.

How much funding has Entvin raised?

Entvin has raised 500000.

Who founded Entvin?

Entvin was founded by Rishabh Arya.

  • Rishabh Arya - Co-Founder
Location
San Francisco, United States
Founded
2022
Funding
500000
Employees
11 employees
Major Investors
Y Combinator
Looking for specific startups?
Try our free semantic startup search

Entvin

Score: 100/100
AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

Entvin provides AI-powered solutions that automate the generation of regulatory and scientific reports for pharmaceutical R&D, reducing report creation time from weeks to just minutes. By integrating with global regulatory databases and leveraging proprietary LLM models, Entvin enhances compliance and accelerates drug development timelines for generic pharma and biologics.

entvin.com2K+
cb
Crunchbase
Founded 2022San Francisco, United States

Funding

$

Estimated Funding

$500K+

Major Investors

Y Combinator

Team (10+)

Aaryan Singh

Founding Member

Rishabh Arya

Co-Founder

Company Description

Problem

Pharmaceutical R&D teams, particularly those focused on generic drugs and biologics, face challenges in navigating disparate global regulatory and scientific data sources. The process of compiling comprehensive regulatory and scientific reports is time-intensive, often taking weeks to complete, which delays drug development timelines.

Solution

Entvin provides an AI-powered platform that automates the generation of regulatory and scientific reports for pharmaceutical R&D, significantly reducing report creation time. The platform integrates with global regulatory databases, scientific literature repositories, and patent databases, providing a unified interface for accessing real-time updates. By leveraging proprietary large language models (LLMs), Entvin intelligently extracts relevant information from documents, automatically updates reports as new information becomes available, and offers data-backed recommendations for literature review and experimental designs. This enables R&D teams to accelerate drug development, enhance compliance, and improve research quality.

Features

Automated R&D report generation, reducing creation time from weeks to minutes

Integration with major regulatory databases (FDA, EMA, PMDA, etc.) for real-time updates

Access to vast scientific literature repositories and patent databases

AI-driven R&D assistant for data-backed recommendations and insights

Secure, private cloud environment for hyper-secure deployment

SOC2, ISO, HIPAA, and GDPR certifications for regulatory compliance

Secure user data management with robust security for user activity logs and data

Target Audience

Entvin primarily targets R&D teams in generic pharmaceutical and biologics companies, as well as formulation scientists and regulatory affairs professionals.

Revenue Model

Entvin operates on a subscription-based model, offering tiered pricing plans based on usage and features.